NCT00290550终止2 期
A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 22
- 主要终点
- Efficacy of MK0457 as a 5 day infusion as measured by radiological exams at baseline and after every other cycle of treatment. After 3 post-treatment radiological assessments, response will be measured after every third cycle.
研究概览
简要总结
This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are at least 18 years of age with cancer of the lung and who have had either no previous treatment or 1 previous treatment for advanced cancer of the lung. Certain other treatments may also be allowed (prior cytotoxic chemotherapy in the adjuvant setting)
排除标准
- •Patients who have had treatment with any investigational therapy within the past 30 days are not eligible.
- •Patients who have had a disease or medical condition that is not controlled will not be eligible.
- •Patients who are pregnant or breastfeeding are not eligible.
研究组 & 干预措施
1
Other
MK-0457
干预措施: MK0457 (Drug)
结局指标
主要结局
Efficacy of MK0457 as a 5 day infusion as measured by radiological exams at baseline and after every other cycle of treatment. After 3 post-treatment radiological assessments, response will be measured after every third cycle.
时间窗: 5 Days
次要结局
- Safety and tolerability as measured by duration, intensity (grade) and time of onset of toxicity.(5 Days)
研究者
相似试验
已完成
2 期
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)HCV InfectionNCT03379506Merck Sharp & Dohme LLC57
已完成
1 期
KRN5500 in Treating Patients With Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00017238National Cancer Institute (NCI)40
已完成
1 期
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease PatientsSafety IssuesToleranceNCT06189170Kariya Pharmaceuticals88
已完成
不适用
Anti-tumor efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural EffusioNeoplasmsKCT0003232Asan Medical Center63
终止
1 期
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT01268059MedImmune LLC99